DOPAMINE DEPENDENT DECREASE IN ENKEPHALIN AND SUBSTANCE-P LEVELS IN BASAL GANGLIA REGIONS OF POSTMORTEM PARKINSONIAN BRAINS

被引:41
作者
SIVAM, SP
机构
[1] Department of Pharmacology and Toxicology, Indiana University School of Medicine, Gary, IN 46408
关键词
D O I
10.1016/0143-4179(91)90148-C
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study examined whether a relationship exists between the degree of dopamine (DA) loss and the changes in opioid (Met5-enkephalin, ME; dynorphin A (1-8) (DYN) or tachykinin (substance P, SP) peptidergic systems in basal ganglia (caudate and putamen) and limbic (frontal cortex) regions of postmortem tissue samples derived from patients who died of Parkinson's disease (PD). The levels of ME, SP and DYN were determined by radioimmunoassays. The levels of DA and 5-hydroxytryptamine (5-HT) and their metabolites were determined by HPLC with electrochemical detection. The degree of loss of DA in PD tissues was classified into two major categories, those with less than 80% and those with more than 80% loss as compared to control. The results reveals that only the category with greater than 80% DA loss exhibited lower levels of ME in caudate and SP in putamen whereas no differences were observed in the levels of DYN in these regions. The frontal cortical region exhibited no changes in the levels of peptides. In other studies, experimental DA deficiency in rodents induced by neurotoxin such as 6-hydroxydopamine (6-OHDA) produced an increase in ME and a decrease in SP in basal ganglia. However, the levels of both peptides were lower in postmortem Parkinsonian basal ganglia in the present study. It appears that there is a DA-dependent, secondary loss of enkephalin and tachykinin peptides in PD. In view of the involvement of these peptidergic systems in the regulation of behaviour, movement, memory and other functions, derangements in these systems should be considered as additional factors in the progression of symptoms of PD.
引用
收藏
页码:201 / 207
页数:7
相关论文
共 40 条
[1]   PEPTIDES AND PARKINSONS-DISEASE [J].
AGID, Y ;
JAVOYAGID, F .
TRENDS IN NEUROSCIENCES, 1985, 8 (01) :30-35
[2]  
ANGULO JS, 1986, EUR J PH ARKM, V140, P341
[3]  
BANNON MJ, 1986, J BIOL CHEM, V261, P6640
[4]   ADRENAL GRAFTING FOR PARKINSONS-DISEASE - A ROLE FOR SUBSTANCE-P [J].
BARKER, R .
INTERNATIONAL JOURNAL OF NEUROSCIENCE, 1989, 46 (1-2) :47-51
[5]   SUBSTANCE-P AND PARKINSONS-DISEASE - A CAUSAL RELATIONSHIP [J].
BARKER, R .
JOURNAL OF THEORETICAL BIOLOGY, 1986, 120 (03) :353-362
[6]  
BREESE GR, 1984, J PHARMACOL EXP THER, V231, P343
[7]   SUBSTANCE-P-LIKE IMMUNOREACTIVITY IN BRAINS WITH PATHOLOGICAL FEATURES OF PARKINSONS AND ALZHEIMERS DISEASES [J].
CLEVENS, RA ;
BEAL, MF .
BRAIN RESEARCH, 1989, 486 (02) :387-390
[8]   IMMUNOCYTOCHEMICAL STUDIES OF SUBSTANCE-P AND MET-ENKEPHALIN IN THE BASAL GANGLIA AND SUBSTANTIA NIGRA IN HUNTINGTONS, PARKINSONS AND ALZHEIMERS DISEASES [J].
GRAFE, MR ;
FORNO, LS ;
ENG, LF .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1985, 44 (01) :47-59
[9]  
GRAYBIEL AM, 1986, CHEM NEUROANATOMY, P427
[10]   RESPONSE OF STRIATONIGRAL SUBSTANCE-P SYSTEMS TO A DOPAMINE RECEPTOR AGONIST AND ANTAGONIST [J].
HANSON, G ;
ALPHS, L ;
PRADHAN, S ;
LOVENBERG, W .
NEUROPHARMACOLOGY, 1981, 20 (06) :541-548